Efficacy and safety of repeated dosing of netupitant, a neurokinin‐1 receptor antagonist, in treating overactive bladder

Abstract

The study failed to demonstrate superiority of netupitant versus placebo in decreasing OAB symptoms, despite a trend favoring netupitant 100 mg. There were no safety concerns with daily administration of netupitant over 8 weeks.

Emerging drugs for overactive bladder

“…It reduced urinary frequency and urgency episodes in the aprepitant group compared with placebo. Drug-related clinical adverse effects were more common in the aprepitant group [66]. Netupitant, another NK1 antagonist, failed to be superior to placebo in a Phase II study.…”

New concepts for the treatment of male lower urinary tract symptoms

“…For neurokinins as well as for prostaglandins, there was good preclinical evidence that they might be of value in treating LUTS [78][79][80]. But, recently published clinical data showed no meaningful effect of neither netupitant, a neurokinin receptor antagonist, nor ONO-8539, a prostaglandin (subtype EP1) receptor antagonist, in LUTS [81,82 && ,83 && ].…”

Netupitant/Palonosetron

“…The pharmacokinetics of netupitant were not affected by the presence of erythromycin. 26 Coadministration of netupitant 300 mg and dexamethasone (20 mg on day 1 followed by 8 mg twice daily on days 2 to 4) increased dexamethasone's AUC 0-24 by 72% on day 1, AUC [24][25][26][27][28][29][30][31][32][33][34][35][36] by 143% on day 2, AUC 84-108 by 140%, and AUC 84-inf by 140% compared with dexamethasone alone. The C max of dexamethasone was increased by 11% on day 1, by 66% on day 2, and by 75% on day 4.…”